Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10370 +/- Adebrelimab + Chemotherapy vs Tislelizumab + Chemotherapy in 1L KRAS G12C NSCLC
NCT07822542Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Primary completion
- May 2030
01
Overview
Phase 3, randomised, open-label trial of hs-10370 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Progression-Free Survival at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hs-10370
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07822542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822542.